Brii Biosciences Limited (BRIBF)
USD 0.13
(0.0%)
USD 0.13
(0.0%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | -594.01 Million | -496.27 Million | -879.45 Million | -403.71 Million | -67.27 Million |
| Net Income | -184.37 Million | -489.78 Million | -4.19 Billion | -1.28 Billion | -521.02 Million |
| Depreciation & Amortization | 15.67 Million | 17.03 Million | 17.26 Million | 14.2 Million | 7.49 Million |
| Deferred income taxes | - | 11.88 Million | -44.79 Million | 15.01 Million | -5.29 Million |
| Stock-based compensation | 64.22 Million | 77.92 Million | 79.37 Million | 29.48 Million | 23.38 Million |
| Change in working capital | -120.73 Million | -76.99 Million | -333.74 Million | 471.45 Million | 25.63 Million |
| Other non-cash items | -107.52 Million | -36.35 Million | 3.59 Billion | 349.63 Million | 402.54 Million |
| Investing Cash Flow | -104.35 Million | -1.43 Billion | -475.75 Million | -43.65 Million | -92.78 Million |
| Investments in PPE | -49.6 Million | -139.29 Million | -1.02 Million | - | -24.14 Million |
| Acquisitions | 56.02 Million | 139.29 Million | 1.62 Million | - | 143 Thousand |
| Investment purchases | -3.48 Billion | -2.1 Billion | -499.64 Million | -196.22 Million | -71.55 Million |
| Sales/Maturities of investments | 3.26 Billion | 774.81 Million | 20.1 Million | 153.69 Million | 5.09 Million |
| Other Investing Activities | 1.14 Million | -106.07 Million | 3.19 Million | -1.12 Million | -2.31 Million |
| Financing Cash Flow | -10.97 Million | -3.04 Million | 3.23 Billion | 657 Million | 518.34 Million |
| Debt repayment | -9.5 Million | -8.96 Million | -9.74 Million | -6.78 Million | -200 Thousand |
| Dividends payments | - | - | - | - | - |
| Common Stock Repurchased | -1.16 Million | -678 Thousand | - | - | - |
| Common Stock Issuance | 179 Thousand | 7.44 Million | 2.32 Billion | 144 Thousand | - |
| Other Financing Activities | -315 Thousand | -9.81 Million | 904.9 Million | 656.85 Million | 518.54 Million |
| Accounts receivables | - | - | - | - | - |
| Accounts payables | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Other working capital | -33.14 Million | -76.99 Million | -333.74 Million | 471.45 Million | 25.63 Million |
| Cash at beginning of period | 1.19 Billion | 2.85 Billion | 1.03 Billion | 880.35 Million | 521.11 Million |
| Cash at end of period | 489.65 Million | 1.19 Billion | 2.85 Billion | 1.03 Billion | 880.35 Million |
| Capital Expenditure | -49.6 Million | -139.29 Million | -1.02 Million | - | -24.14 Million |
| Effect of forex changes on cash | 8.41 Million | 267.96 Million | -54.79 Million | -55.02 Million | 950 Thousand |
| Net cash flow / Change in cash | -700.92 Million | -1.66 Billion | 1.82 Billion | 154.6 Million | 359.24 Million |
| Free Cash Flow | -643.62 Million | -635.57 Million | -880.48 Million | -403.71 Million | -91.42 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -19.3 Million | -19.42 Million | -184.37 Million | 1.06 Million | 1.03 Million | -27.4 Million |
| Depreciation & Amortization | 415.69 Thousand | 418.39 Thousand | 15.67 Million | 504.31 Thousand | 490.27 Thousand | 1.22 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 215.96 Thousand | 217.36 Thousand | 64.22 Million | 2.21 Million | 2.14 Million | - |
| Change in working capital | - | - | -120.73 Million | -2.33 Million | -2.26 Million | - |
| Other non-cash items | 3.13 Million | 3.15 Million | -107.52 Million | -18.36 Million | -17.85 Million | -19.08 Million |
| Investing Cash Flow | 27.1 Million | 27.27 Million | -104.35 Million | 17.54 Million | 17.05 Million | -54.34 Million |
| Investments in PPE | -52.63 Thousand | -52.97 Thousand | -49.6 Million | -6.86 Million | - | - |
| Acquisitions | - | - | 56.02 Million | - | - | - |
| Investment purchases | -14.23 Million | - | -3.48 Billion | -298.5 Million | - | -183.14 Million |
| Sales/Maturities of investments | 64.44 Million | - | 3.26 Billion | 330.08 Million | - | 128.26 Million |
| Other Investing Activities | 27.15 Million | 27.33 Million | 1.14 Million | 17.54 Million | 17.05 Million | 525.74 Thousand |
| Financing Cash Flow | -304.23 Thousand | -306.21 Thousand | -10.97 Million | -436.4 Thousand | -424.25 Thousand | -653.27 Thousand |
| Debt repayment | - | - | -9.5 Million | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | -1.16 Million | -81.85 Thousand | -79.57 Thousand | - |
| Common Stock Issuance | 5965.66 | - | 179 Thousand | 5935.00 | - | 18.75 Thousand |
| Other Financing Activities | -304.23 Thousand | -306.21 Thousand | -315 Thousand | -354.54 Thousand | -344.67 Thousand | -672.03 Thousand |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | - | - | -33.14 Million | -2.33 Million | -2.26 Million | - |
| Cash at beginning of period | 17.05 Million | - | 1.19 Billion | 67.35 Million | 67.18 Million | 130.04 Million |
| Cash at end of period | 100.33 Million | 11.53 Million | 489.65 Million | 17.05 Million | 67.33 Million | 67.35 Million |
| Capital Expenditure | -52.63 Thousand | -52.97 Thousand | -49.6 Million | -6.86 Million | - | - |
| Effect of forex changes on cash | 200.07 Thousand | 201.37 Thousand | 8.41 Million | -32.05 Thousand | -31.16 Thousand | 40.03 Million |
| Net cash flow / Change in cash | 83.28 Million | 11.53 Million | -700.92 Million | -50.3 Million | 147.65 Thousand | -62.68 Million |
| Free Cash Flow | -15.58 Million | -15.68 Million | -643.62 Million | -23.78 Million | -16.45 Million | -47.71 Million |
600642
4444
ALUCON
FME
7846
4732